Company BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 08/07/2025 pm IST			5-day change	1st Jan Change
184.80 ^SEK	-0.48%		+3.41%	-7.37%

17/06	Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta	FW
13/06	BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review	MT

Business description: BioArctic AB

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Number of employees: 116

Sales by Activity: BioArctic AB

Fiscal Period: December	2020	2021	2022	2023	2024
Biotechnology	6.52Cr	2.57Cr	23Cr	62Cr	26Cr

See all business segments

Geographical breakdown of sales: BioArctic AB

Fiscal Period: December	2020	2021	2022	2023	2024
North America	-	-	-	-	14Cr
Asia	2.85Cr	1.47Cr	17Cr	62Cr	10Cr
Europe	3.38Cr	84.66L	5.85Cr	-	1.17Cr
Rest of World	-	-	-	-	47T

See all geographic segments

Executive Committee: BioArctic AB

Manager	Title	Age	Since
Gunilla Christina Osswald CEO	Chief Executive Officer	64	01/01/2013
Anders Martin-Löf DFI	Director of Finance/CFO	54	01/06/2023
Johanna Fälting CTO	Chief Tech/Sci/R&D Officer	53	01/01/2012
Tomas Odergren CTO	Chief Tech/Sci/R&D Officer	66	01/01/2019
Christer Möller CTO	Chief Tech/Sci/R&D Officer	66	01/01/2006

See BIOARCTIC AB governance

Composition of the Board of Directors: BioArctic AB

Director	Title	Age	Since
Pär Lars Gellerfors BRD	Director/Board Member	78	24/01/2003
Lars Gunnar Lannfelt CHM	Chairman	76	28/01/2003
Eugen Steiner CHM	Chairman	71	01/06/2023
Åke Mikael Smedeby BRD	Director/Board Member	57	-
Charlotta Ljungqvist BRD	Director/Board Member	64	06/05/2021
Cecilia Marie Edström BRD	Director/Board Member	59	01/06/2023

Composition of the Board of Directors

Shareholders: BioArctic AB

Name	Equities	%	Valuation
Lars Gunnar Lannfelt 28.35 %	2,08,85,052	28.35 %	392 M kr
Pär Lars Gellerfors 18.11 %	1,33,43,201	18.11 %	250 M kr
Fjärde AP-fonden 7.356 %	54,18,493	7.356 %	102 M kr
Swedbank Robur Fonder AB 4.252 %	31,31,849	4.252 %	59 M kr
RA Capital Management LP 4.233 %	31,17,736	4.233 %	58 M kr

Name	Equities	%	Valuation
Lars Gunnar Lannfelt 60 %	86,39,998	60 %	162 M kr
Pär Lars Gellerfors 40 %	57,59,998	40 %	108 M kr

List of BIOARCTIC AB shareholders

Company details: BioArctic AB

BioArctic AB

Warfvinges väg 35

112 51, Stockholm

+46 86 95 69 30

http://www.bioarctic.se

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BIOARCTIC AB	-0.48%	+3.41%	-16.30%	+131.00%	173.06Cr
LONZA GROUP AG	-0.43%	-1.66%	+10.63%	+0.40%	4.95TCr
CELLTRION, INC.	-1.85%	+9.96%	+3.15%	+6.30%	2.89TCr
BEONE MEDICINES LTD.	+1.44%	-0.28%	+69.36%	+29.53%	2.85TCr
IQVIA HOLDINGS INC.	+1.24%	+1.14%	-21.28%	-25.02%	2.81TCr
EUROFINS SCIENTIFIC SE	-1.00%	-1.26%	+24.51%	-22.51%	1.27TCr
ICON PUBLIC LIMITED COMPANY	+2.70%	+1.81%	-52.77%	-30.45%	1.17TCr
ASCENDIS PHARMA A/S	-4.44%	-2.23%	+23.24%	+79.65%	1.07TCr
QIAGEN N.V.	+0.67%	-0.75%	+15.61%	-6.57%	1.03TCr
TEMPUS AI, INC.	+0.86%	-1.57%	+76.23%	-	1TCr
Average	-0.22%	+0.26%	+13.24%	+18.04%	1.92TCr
Weighted average by Cap.	-0.11%	+0.15%	+14.76%	+3.88%